Recombinant AAV is a powerful vector for gene delivery—but its full potential is held back by the limitations of plasmid DNA. Touchlight’s whitepaper explores how dbDNA™, a synthetic, enzymatically produced DNA technology, overcomes key barriers in AAV manufacture—offering a scalable, high-fidelity, and antibiotic-free alternative to traditional plasmid production.

This whitepaper features a compelling case study from an Innovate UK-funded collaboration with Cobra Biologics, demonstrating that AAV vectors made with dbDNA™ deliver comparable titres and in vivo expression to those made with plasmids—without the associated drawbacks.

In this white paper, you’ll learn:

• How to accelerate timelines with rapid, cell-free GMP production
• How to scale efficiently without compromising quality or consistency
• How to enhance safety by eliminating bacterial sequences and antibiotic resistance genes

Download the white paper to explore the data.